BIRC3 and plasma cell myeloma: MMCLs were treated with different concentrations of inhibitors or control compound for 16 h, and then NFkB activity was measured by determining the RNA expression levels of 3 NFkB target genes - cIAP2, TNFAIP3, NFKB2, which are the most sensitive target genes in myeloma cells [15].